Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelic microdosing benefits and challenges: an empirical codebook
Thomas Anderson, Rotem Petranker, Adam Christopher, et al.
Harm Reduction Journal (2019) Vol. 16, Iss. 1
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 163
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Laura Kaertner, Michael B. Steinborn, Hannes Kettner, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 111
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field
Vince Polito, Paul Liknaitzky
Neuroscience & Biobehavioral Reviews (2022) Vol. 139, pp. 104706-104706
Open Access | Times Cited: 70
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 2
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, et al.
European Neuropsychopharmacology (2020) Vol. 41, pp. 81-91
Open Access | Times Cited: 95
Psychedelic Microdosing: A Subreddit Analysis
Toby Lea, Nicole Amada, Henrik Jungaberle
Journal of Psychoactive Drugs (2019) Vol. 52, Iss. 2, pp. 101-112
Closed Access | Times Cited: 91
Psychedelic Microdosing: Prevalence and Subjective Effects
Lindsay P. Cameron, Angela Nazarian, David E. Olson
Journal of Psychoactive Drugs (2020) Vol. 52, Iss. 2, pp. 113-122
Open Access | Times Cited: 83
Psychedelics and health behaviour change
Pedro J. Teixeira, Matthew W. Johnson, Christopher Timmermann, et al.
Journal of Psychopharmacology (2021) Vol. 36, Iss. 1, pp. 12-19
Open Access | Times Cited: 60
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial
Robin J. Murphy, Rachael L. Sumner, William J. Evans, et al.
Biological Psychiatry (2023) Vol. 94, Iss. 6, pp. 511-521
Open Access | Times Cited: 30
Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine
Conor H. Murray, Joel Frohlich, Connor J. Haggarty, et al.
Neuropsychopharmacology (2024)
Closed Access | Times Cited: 13
Microdosing Psychedelics: Current Evidence From Controlled Studies
Robin J. Murphy, Suresh Muthukumaraswamy, Harriet de Wit
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 500-511
Open Access | Times Cited: 12
The therapeutic potential of microdosing psychedelics in depression
Kim P. C. Kuypers
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 60
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders
Toby Lea, Nicole Amada, Henrik Jungaberle, et al.
Psychopharmacology (2020) Vol. 237, Iss. 5, pp. 1521-1532
Closed Access | Times Cited: 56
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 6, pp. 612-622
Closed Access | Times Cited: 56
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Simon Vann Jones, Allison O’Kelly
Frontiers in Synaptic Neuroscience (2020) Vol. 12
Open Access | Times Cited: 51
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Kate Corrigan, Maeve Haran, Conor McCandliss, et al.
Irish Journal of Medical Science (1971 -) (2021) Vol. 191, Iss. 3, pp. 1385-1397
Open Access | Times Cited: 47
Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies
Javier Calleja‐Conde, José Á. Morales-García, Víctor Echeverry‐Alzate, et al.
Addiction Biology (2022) Vol. 27, Iss. 6
Open Access | Times Cited: 31
Psilocybin’s effects on cognition and creativity: A scoping review
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 635-648
Open Access | Times Cited: 17
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
Genís Oña, José Carlos Bouso
Neuroscience & Biobehavioral Reviews (2020) Vol. 119, pp. 194-203
Closed Access | Times Cited: 44
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention
Rotem Petranker, Thomas Anderson, Larissa J. Maier, et al.
Journal of Psychopharmacology (2020) Vol. 36, Iss. 1, pp. 85-96
Open Access | Times Cited: 40
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Jack E. Henningfield, Marion A. Coe, Roland R. Griffiths, et al.
Neuropharmacology (2022) Vol. 218, pp. 109220-109220
Open Access | Times Cited: 25
A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond
Marco Pepe, Mohsen Hesami, Karla A. de la Cerda, et al.
Biotechnology Advances (2023) Vol. 69, pp. 108247-108247
Closed Access | Times Cited: 15
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research
Vince Polito, Paul Liknaitzky
Journal of Psychopharmacology (2024) Vol. 38, Iss. 8, pp. 701-711
Open Access | Times Cited: 5
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Sam Gandy
Journal of Psychedelic Studies (2019) Vol. 3, Iss. 3, pp. 280-287
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top